Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

FDA Panel Votes Against Cough Medicine Scheduling

By Drug Discovery Trends Editor | September 15, 2010

WASHINGTON (AP) – A panel of medical experts said that cough medicines like Robitussin and Nyquil should continue to be sold over-the-counter, despite increased abuse among teenagers that has prompted calls to restrict sales of the products.

The Food and Drug Administration panel voted 15-9 against a proposal that would require a doctor’s note to buy medicines containing dextromethorphan, an ingredient found in more than 100 over-the-counter medications.

The FDA is not bound to follow the group’s advice, though it often does. Specifically, panelists were asked if the ingredient should be “scheduled,” a regulatory move designed to decrease access to drugs with high potential for abuse.

“For me there was no data to show us that scheduling this product would decrease abuse,” said panelist Janet Engle, professor and department head of pharmacy practice at the University of Illinois.

Abuse of dextromethorphan, dubbed “robotripping,” is popular among teenagers as an inexpensive way to get high, but it carries risks, including elevated blood pressure, heart rate and fever. Abusers can also suffer side effects from other ingredients mixed in cough medicines, such as acetaminophen, which can cause liver damage.

Medical complications from the behavior are on the rise with nearly 8,000 emergency room visits reported in 2008. That was up more than 70 percent from reports in 2004.

“Many teenagers are thinking that because it’s a legal drug it must be safer to abuse, and that’s why we’re also seeing a growing trend in prescription drug abuse,” said Engle, in a telephone interview with The Associated Press.

The FDA agreed to revisit how it regulates the medicines at the behest of the Drug Enforcement Agency, which suggested making them prescription drugs.

But many of FDA’s panelists said making the drugs prescription-only would go too far – creating an enormous amount of extra work for doctors and pharmacists.

Dextromethorphan products were purchased by more than 40 million U.S. households last year. Popular brands containing dextromethorphan include Wyeth’s Dimetapp, Bayer’s Alka Seltzer Flu Plus and Procter & Gamble’s Vicks cough medicines. The drug is available in pills, gel caps, liquids and other forms.

Surveys by cough medicine manufacturers show that less than 2 percent of youngsters ages 12 to 17 reported abusing dextromethorphan in 2008, far less than those abusing marijuana or prescription painkillers.

The Consumer Healthcare Products Association supports prohibiting sales of the medicines to people under age 18. Such age restrictions require legal changes, and the industry trade association has lobbied on the issue at the state and federal levels.

Date: September 14, 2010
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE